Holen Sie sich die Stockscreener-App
6.88
1.78%
0.12
Handel nachbörslich:
7.01
0.13
+1.89%
Schlusskurs vom Vortag:
$6.76
Offen:
$6.85
24-Stunden-Volumen:
1.24M
Relative Volume:
0.40
Marktkapitalisierung:
$765.47M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-6.1429
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
+5.85%
1M Leistung:
+16.02%
6M Leistung:
+174.10%
1J Leistung:
-23.98%
1-Tages-Spanne:
$6.60
$7.15
1-Wochen-Bereich:
$6.265
$7.15
52-Wochen-Spanne:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
6.88 | 713.18M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Advanced analytics toolkit walkthrough for Tango Therapeutics Inc.Quarterly Market Review & Real-Time Stock Price Movement Reports - Newser
Using Python tools to backtest Tango Therapeutics Inc. strategiesMarket Risk Report & Reliable Trade Execution Plans - Newser
What’s next for Tango Therapeutics Inc. stock priceBull Run & Fast Exit/Entry Strategy Plans - Newser
Tango Therapeutics Inc. stock chart pattern explained [Weekly Trend Recap]Growth Focused Stock Pick Reports - Newser
What machine learning models say about Tango Therapeutics Inc.2025 Key Lessons & Risk Controlled Stock Alerts - Newser
What Fibonacci levels say about Tango Therapeutics Inc. rebound2025 Market Outlook & Expert Curated Trade Setups - Newser
Why Tango Therapeutics Inc. stock attracts strong analyst attentionFree Fast Exit and Entry Strategy Guide - Newser
Is Tango Therapeutics Inc. stock a value trapBig Profit Trading Alerts - thegnnews.com
What candlestick patterns are forming on Tango Therapeutics Inc.Free Reliable Chart-Based Trade Entries - Newser
Technical Charts Suggest Momentum Shift in Tango Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - 선데이타임즈
How moving averages guide Tango Therapeutics Inc. tradingWeekly Trend Screener with Momentum Picks - Newser
Tango Therapeutics Inc. Company Revenue and Profit Trends: A Deep DivePattern Breakout Prediction for Short Term - Newser
Need To Know: Analysts Are Much More Bullish On Tango Therapeutics, Inc. (NASDAQ:TNGX) - 富途牛牛
How high can Tango Therapeutics Inc. stock price go in 2025Oversold Reversal Picks with Buy Zone - Newser
Will Tango Therapeutics Inc. see short term momentumTrade Plan With Low Risk High Return - Newser
Tango Therapeutics Inc. recovery potential after sell offDaily Market Momentum and Pressure Analysis - Newser
Cantor Fitzgerald Issues Positive Forecast for TNGX Earnings - Defense World
Full technical analysis of Tango Therapeutics Inc. stockFree Strong Buy With Technical Confidence - Newser
Price action breakdown for Tango Therapeutics Inc.Volume Spike Detection for Early Breakouts - Newser
Wedbush Forecasts Stronger Earnings for Tango Therapeutics - Defense World
Tango Therapeutics: Guggenheim Raises PT to $10, Maintains Buy Rating - AInvest
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Bank of New York Mellon Corp Acquires 10,213 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics 2025 Q2 Earnings Misses Targets as Net Loss Widens 52% - AInvest
Tango Therapeutics Reports Q2 2025 Financial Results - TipRanks
Tango (TNGX) Q2 Revenue Drops 52% - The Globe and Mail
Tango (TNGX) Q2 Revenue Drops 52% - The Motley Fool
Revolution Medicines shares rise 2.80% intraday after Tango Therapeutics reported dosing first patient in combination trial with Revolution Medicines RAS(ON) inhibitors. - AInvest
Navigating the Crossroads: Tango Therapeutics' Financial Resilience and the Road to Long-Term Value Creation - AInvest
Tango Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Tango Therapeutics earnings matched, revenue fell short of estimates - Investing.com
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Tango Therapeutics, Inc. SEC 10-Q Report - TradingView
Tango Therapeutics Q2 revenue drops, net loss widens - MarketScreener
Tango Therapeutics Advances Cancer Pipeline: First Patients Dosed in Brain Cancer and RAS Inhibitor Trials - Stock Titan
Analyzing Tango Therapeutics Inc. with risk reward ratio chartsLong Term Equity Screener with Safety Metrics - Newser
Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely? - Yahoo Finance
Is Tango Therapeutics Inc. stock bottoming outSmart Trade Forecast Based on Neural Logic - Newser
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):